GLP-1 Revolution
by Amaltash Advisors LLC
$28.87
-2.10% past month
Nov 16, 2026
$28.86-0.10%
Pfizer closed down 0.10%, a much smaller move than the cohort's. Comparable Pharmaceutical Preparations companies fell 0.77% on average, with all 6 of 6 lower . The company's shares therefore held up better than its comparable companies on the day .
Nov 13, 2026
$28.89+0.21%
Nov 12, 2026
$28.83-2.11%
Pfizer fell 2.11% on a day when comparable pharmaceutical preparations companies moved -0.80% on average, with all 6 of 6 falling . The decline was therefore larger than the cohort's average move. Seeking Alpha published a piece arguing that $1.5bn of Blackstone funding did not make berobenatide a winning obesity drug .
Nov 11, 2026
$29.45+0.31%
Seeking Alpha reported that Blackstone would provide Pfizer up to $1.5B to advance berobenatide, a monthly GLP-1 for weight loss, with milestone payments tied to approval and sales . The shares closed up 0.31%.
Nov 10, 2026
$29.36+0.44%
Nov 9, 2026
$29.23-0.54%
Pfizer closed down 0.54% while comparable pharmaceutical preparations companies rose 0.84% on average, with five of six rising . The move was therefore not shared by the cohort, and the day's other items offered no reported event to account for it.
Nov 6, 2026
$29.39-1.64%
Pfizer fell 1.64% while comparable pharmaceutical companies moved -0.48% on average, with 3 of 6 falling and 3 rising . The decline was therefore larger than the cohort's and was not matched across the group. Seeking Alpha reported that Democratic lawmakers were seen planning probes into Trump drug pricing deals once House and Senate control shifts .
Closing prices for PFE. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.
As of Nov 16, 2026, Pfizer Inc. is 6.3% below its 52-week high. Its largest decline in the period shown was -64.8% (Dec 16, 2021 to Apr 10, 2025).
As of Nov 16, 2026, Pfizer Inc. closed 6.3% below its 52-week closing high, set on Nov 4, 2026.
Pfizer Inc. fell 64.8% from Dec 16, 2021 to Apr 10, 2025, close to close, the largest decline in daily data since Nov 18, 2021. It had not closed back above that high as of Nov 16, 2026.
Learn how max drawdown is measured, and how past market drawdowns played out.
Daily closing prices from Nov 18, 2021 to Nov 16, 2026, adjusted for splits but not dividends. Past price movements do not predict future results.
How much would it be worth today? $1,000 invested in Pfizer Inc. (PFE) 10 years ago, at the Nov 30, 2016 close, would be worth about $898 today, based on the Nov 16, 2026 close — a loss of $102 (-10.2%), dividends not included. Along the way it fell as much as 64.8% from a high, between Dec 16, 2021 and Apr 10, 2025. Before Nov 2021 this uses monthly highs and lows.
Return calculator
Worth today, at the Nov 16, 2026 close
$10,927
-$1,973 · -15.3%The cash line is the same deposits earning nothing. A savings account would usually have paid some interest.
Past performance of PFE's closing prices (split-adjusted; dividends not included). It ignores fees, taxes and trading costs. The results change as prices update and with the amounts you enter. Past results do not predict future results, and a single stock can fall hard. We show this for every asset in our directory; it is not a recommendation to buy or sell PFE.
Try the full investment calculatorThe coffee test
A $5 coffee every workday comes to about $100 a month. Over 5 years that's 1,200 coffees, or $6,000.
The same $100 a month put into PFE since November 2021 would be worth $5,488 today.
This time, the coffee was the better buy.
Past performance, month-end prices. Not a forecast.
| Invested | Start date | PFE price then | $1,000 → | $10,000 → | Change |
|---|---|---|---|---|---|
| 1 year | Nov 28, 2025 | $25.74 | $1,121 | $11,212 | +12.1% |
| 3 years | Nov 30, 2023 | $30.47 | $947 | $9,472 | -5.3% |
| 5 years | Nov 30, 2021 | $53.73 | $537 | $5,371 | -46.3% |
| 10 years | Nov 30, 2016 | $32.14 | $898 | $8,979 | -10.2% |
$10,000 invested in Pfizer Inc. (PFE) at the Nov 30, 2016 close would have been worth about $8,979 at the Nov 16, 2026 close — a loss of $1,021 (-10.2%), dividends not included.
PFE closed at $32.14 on Nov 30, 2016 (split-adjusted). It closed at $28.86 on Nov 16, 2026.
Putting $100 into PFE at each month-end close from Nov 30, 2016 — 120 purchases, $12,000 in total — would have been worth about $10,119 at the Nov 16, 2026 close: a loss of $1,881 (-15.7%), dividends not included.
PFE closed at $28.86 on Nov 16, 2026. A year earlier it closed at $25.06 on Nov 14, 2025, so it is up 15.2% over that year. Five years earlier it closed at $43.74 on Oct 29, 2021 (down 34.0% since then). Its highest close in the year to Nov 16, 2026 was $30.79 on Nov 4, 2026, and its lowest was $23.67 on Jun 25, 2026. These are split-adjusted closing prices; dividends are not included.
PFE last closed at $28.86 on Nov 16, 2026. This page is updated once a day, so it does not show live prices.
Over one year, from $25.06 on Nov 14, 2025 to $28.86 on Nov 16, 2026, it was up 15.2%. Over five years, from $43.74 on Oct 29, 2021 to $28.86 on Nov 16, 2026, it was down 34.0%. These are split-adjusted closing prices; dividends are not included.
As of Nov 16, 2026, Pfizer Inc. had a market value (market cap) of about $164.7 billion and a price-to-earnings (P/E) ratio of 36.6.
Pfizer is a health care company that makes and sells medicines and vaccines. Its products help prevent and treat many diseases around the world.
We do not tell anyone whether to buy or sell PFE, and past results do not predict future results. Its largest fall from a high since Nov 18, 2021 was 64.8%, from $61.25 on Dec 16, 2021 to $21.59 on Apr 10, 2025. A single stock can lose much of its value, so think about how much you could afford to lose. Our investment calculator shows how past amounts would have changed.
Past performance of PFE's closing prices. Not a forecast. This is general information, not a recommendation to buy or sell PFE.
Try the full investment calculatorThese strategies on Amaltash hold PFE today. We show them so you can see where it is used. This is not a recommendation to invest in any of them.
by Amaltash Advisors LLC
by Amaltash Advisors LLC
This strategy bets on the booming weight-loss and metabolic health revolution — and it goes far beyond just the blockbuster drug makers you've heard about on the news. It builds a diversified basket across the entire ecosystem: companies developing next-generation obesity and diabetes treatments, the diagnostic labs helping doctors identify and monitor patients, the device makers tracking metabolic health, the clinics and care delivery platforms scaling treatment access, and even the insurers reshaping how metabolic disease is covered and reimbursed. The strategy focuses exclusively on companies that have already shown sustained upward price momentum over recent years — it's not trying to pick speculative moonshots, but rather ride names that the market has already started rewarding. The basket rotates and rebalances to keep exposure fresh, leaning into the strongest performers while trimming names that lose their footing. It's long-only and growth-oriented, meaning it profits when these companies rise in value — it does not short or hedge. The personality is opportunistic but not reckless: a built-in drawdown guardrail is designed to protect the portfolio if the sector hits a rough patch, targeting a maximum loss limit so a bad quarter doesn't wipe out a good year. Imagine this scenario: A major insurer announces it will cover GLP-1 treatments broadly. Drug makers surge, but so do the glucose monitors, the telehealth obesity clinics, and the cardiac device companies treating downstream complications. This strategy is already holding across all of those layers — capturing the wave rather than just one drop of it.
View strategy →